Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer

Journal of Surgical Oncology

Volumn 104, Issue 7, 2011, Pages 841-846

  Shao, Wenlong ^a,b,c   Wang, Wei ^a,b,c   Xiong, Xin Guo ^b,c   Cao, Christopher ^d   Yan, Tristan D ^d   Chen, Guoqin ^b   Chen, Hanzhang ^b,c   Yin, Weiqiang ^b,c   Liu, Jun ^b,c   Gu, Yingying ^b   Mo, Mingcong ^b   He, Jianxing ^b,c  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d The Baird Institute of Applied Heart and Lung Surgical Research   (Australia)

Author keywords

MMP 2; MMP 9; non small cell lung cancer; vessel invasion

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; FORMALDEHYDE; GELATINASE A; GELATINASE B;

ADULT; AGED; ARTICLE; BLOOD VESSEL; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80255124887     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22001     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66. (Pubitemid 46148091)
2. Goya T, Asamura H, Yoshimura H, et al.: Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study. Lung Cancer 2005; 50: 227-234. (Pubitemid 41427898)
3. Winter H, van den Engel NK, Rusan M, et al.: Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis 2011; 3: 105-114.
4. Kawai H, Tada A, Kawahara M, et al.: Smoking history before surgery and prognosis in patients with stage IA non-small cell lung cancer-a multicenter study. Lung Cancer 2005; 49: 63-70. (Pubitemid 40798094)
5. Sakao Y, Tomimitsu S, Takeda Y, et al.: Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma. Eur J Cardiothorac Surg 2004; 25: 520-522. (Pubitemid 38376063)
6. Ginsberg RJ, Rubinstein LV,: Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60: 615-623.
7. Port JL, Kent MS, Korst RJ, et al.: Tumor size predicts survival within stage IA non-small cell lung cancer. Chest 2003; 124: 1828-1833. (Pubitemid 37433580)
8. Chang MY, Mentzer SJ, Colson YL, et al.: Factors predicting poor survival after resection of stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg 2007; 134: 850-856. (Pubitemid 47454622)
9. Shoji F, Haro A, Yoshida T, et al.: Prognostic significance of intratumoral blood vessel invasion in pathologic stage IA non-small cell lung cancer. Ann Thorac Surg 2010; 89: 864-869.
10. Bethune G, Bethune D, Ridgway N, et al.: Epidermal growth factor receptor (EGFR) in lung cancer: An overview and update. J Thorac Dis 2010; 2: 48-51.
11. Kerbel RS,: Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000; 21: 505-515. (Pubitemid 30137936)
12. Ray JM, Stetler-Stevenson WG,: The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994; 7: 2062-2072. (Pubitemid 24366302)
13. Fortunato SJ, Menon R,: Screening of novel matrix metalloproteinases (MMPs) in human fetal membranes. J Assist Reprod Genet 2002; 19: 483-486. (Pubitemid 35231181)
14. Stamenkovic I,: Extracellular matrix remodelling: The role of matrix metalloproteinases. J Pathol 2003; 200: 448-464. (Pubitemid 36818245)
15. Hojilla CV, Mohammed FF, Khokha R,: Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003; 89: 1817-1821. (Pubitemid 37533251)
16. Passlick B, Sienel W, Seen-Hibler R, et al.: Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000; 6: 3944-3948.
17. Kumaki F, Matsui K, Kawai T, et al.: Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol 2001; 159: 2125-2135. (Pubitemid 33104267)
18. Cox G, Jones JL, O'Byrne KJ,: Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000; 6: 2349-2355. (Pubitemid 30399202)
19. Herbst RS, Yano S, Kuniyasu H, et al.: Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res 2000; 6: 790-797. (Pubitemid 30159331)
20. Shou Y, Hirano T, Gong Y, et al.: Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer 2001; 85: 1706-1712. (Pubitemid 34081517)
21. Sienel W, Hellers J, Morresi-Hauf A, et al.: Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 2003; 103: 647-651. (Pubitemid 36091469)
22. Martini N,: Mediastinal lymph node dissection for lung cancer. The Memorial experience. Chest Surg Clin N Am 1995; 5: 189-203.
23. Naruke T, Suemasu K, Ishikawa S,: Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 1978; 76: 832-839. (Pubitemid 9084851)
24. Goldstraw P, Crowley J, Chansky K, et al.: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714. (Pubitemid 47357522)
25. Tsuchiya T, Akamine S, Muraoka M, et al.: Stage IA non-small cell lung cancer: Vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer 2007; 56: 341-348. (Pubitemid 46679089)
26. Mino N, Takenaka K, Sonobe M, et al.: Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer. J Surg Oncol 2007; 95: 250-257.
27. Gajra A, Newman N, Gamble GP, et al.: Impact of tumor size on survival in stage IA non-small cell lung cancer: A case for subdividing stage IA disease. Lung Cancer 2003; 42: 51-57. (Pubitemid 37153135)
28. Christian C, Erica S, Morandi U,: The prognostic impact of tumor size in resected stage I non-small cell lung cancer: Evidence for a two thresholds tumor diameters classification. Lung Cancer 2006; 54: 185-191. (Pubitemid 44764925)
29. Rami-Porta R, Ball D, Crowley J, et al.: The IASLC Lung Cancer Staging Project: Proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: 593-602. (Pubitemid 47171780)
30. Goldstein NS, Mani A, Chmielewski G, et al.: Prognostic factors in T1 NO MO adenocarcinomas and bronchioloalveolar carcinomas of the lung. Am J Clin Pathol 1999; 112: 391-402. (Pubitemid 30214780)
31. Macchiarini P, Fontanini G, Hardin MJ, et al.: Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 1993; 106: 80-89. (Pubitemid 23216049)
32. Ichinose Y, Yano T, Asoh H, et al.: Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg 1995; 110: 601-605.
33. Bodendorf MO, Haas V, Laberke HG, et al.: Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma. Lung Cancer 2009; 64: 71-78.
34. Overall CM, Lõpez-Otín C,: Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer 2002; 2: 657-672. (Pubitemid 37328917)
35. Zheng S, Chang Y, Hodges KB, et al.: Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. Anticancer Res 2010; 30: 713-718.
36. Cox G, Jones JL, Andi A, et al.: A biological staging model for operable non-small cell lung cancer. Thorax 2001; 56: 561-566. (Pubitemid 32588536)
37. Yamamura T, Nakanishi K, Hiroi S, et al.: Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. Lung Cancer 2002; 35: 249-255. (Pubitemid 34158657)
38. Ishikawa S, Takenaka K, Yanagihara K, et al.: Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin Cancer Res 2004; 10: 6579-6585. (Pubitemid 39346554)
39. Lin TS, Chiou SH, Wang LS, et al.: Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncol Rep 2004; 12: 717-723.
40. Tanaka H, Nishida K, Sugita K, et al.: Antitumor efficacy of hypothemycin, a new Ras-signaling inhibitor. Jpn J Cancer Res 1999; 90: 1139-1145.
41. Westermarck J, Kähäri VM,: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781-792. (Pubitemid 29220691)
42. Shao WL, Wang DY, He JX,: The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis 2010; 2: 89-99.
43. Zhu CQ, Shih W, Ling CH, et al.: Immunohistochemical markers of prognosis in non-small cell lung cancer: A review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006; 59: 790-800. (Pubitemid 44211740)